Critical Analysis: DocGo (NASDAQ:DCGO) and Establishment Labs (NASDAQ:ESTA)

Establishment Labs (NASDAQ:ESTA) and DocGo (NASDAQ:DCGO) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, risk, profitability and earnings.

Analyst Ratings

This is a summary of current ratings for Establishment Labs and DocGo, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1	1	7	0	2.67
DocGo	1	2	3	0	2.33

Establishment Labs currently has a consensus price target of $90.43, indicating a potential downside of 2.32%. DocGo has a consensus price target of $2.38, indicating a potential upside of 264.71%. Given DocGo’s higher possible upside, analysts plainly believe DocGo is more favorable than Establishment Labs.

Profitability

This table compares Establishment Labs and DocGo’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
DocGo	-62.23%	-44.09%	-29.14%

Volatility and Risk

Establishment Labs has a beta of 1.06, meaning that its share price is 6% more volatile than the S&P 500. Comparatively, DocGo has a beta of 1.02, meaning that its share price is 2% more volatile than the S&P 500.

Institutional & Insider Ownership

72.9% of Establishment Labs shares are owned by institutional investors. Comparatively, 56.4% of DocGo shares are owned by institutional investors. 10.0% of Establishment Labs shares are owned by company insiders. Comparatively, 5.1% of DocGo shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Earnings and Valuation

This table compares Establishment Labs and DocGo”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08 million	12.91	-$51.06 million	($1.49)	-62.13
DocGo	$322.20 million	0.20	-$182.40 million	($1.91)	-0.34

Establishment Labs has higher earnings, but lower revenue than DocGo. Establishment Labs is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.

Summary

Establishment Labs beats DocGo on 10 of the 14 factors compared between the two stocks.

About Establishment Labs

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander. The company sells its products to physicians, hospitals, and clinics through distributors and direct sales force in Europe, the Middle East, Latin America, and Asia. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

About DocGo

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.